CClinicalTrials.gg
CompletedNCT02232464Updated Mar 18, 2015

Disturbed Structural Connectivity of Frontostriatal and Frontoparietal Networks in Adults With ADHD

An observational study in Attention Deficit Hyperactivity Disorder, sponsored by National Taiwan University Hospital. Completed at 1 site in Taiwan. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-18.

Sponsored by National Taiwan University Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
90
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Attention deficit/hyperactivity disorder (ADHD) is a common, impairing, childhood onset neuropsychiatric disorder with executive dysfunctions. The ADHD symptoms and executive deficits may last to adulthood. Our previous studies, like western results, have shown that children with ADHD have disrupted microstructural integrity of frontostriatal fiber pathways and impaired brain activity in frontoparietal network. However, there is lack of data with regards to whether adults with ADHD also demonstrate structural and functional disconnectivity of frontostriatal and frontoparietal networks as compared to healthy controls without ADHD in Asian population and no study has been done to correlate a wide range of executive functions with the connectivity of these two networks.

Specific Aims:

  1. to compare the executive functions, and structural and functional connectivity in frontostriatal and frontoparietal circuitries between adults with ADHD and healthy controls without ADHD;
  2. to correlate the data from structural and functional connectivity, executive functions, and ADHD core symptoms stratifying by the ADHD and controls; and
  3. to explore other circuitries that may involve in ADHD by using whole brain tractography analyses.
02

Conditions studied

  • Attention Deficit Hyperactivity Disorder

Keywords

  • Adult ADHD
  • diffusion spectrum imaging
  • resting-state fMRI
  • frontostriatal circuitries
  • frontoparietal circuitries
  • executive function
03

In context

Hyperkinesis

729 studies on the registry are indexed under Hyperkinesis; 25 are open to participants now.

This study's enrollment of 90 is below the median of 134 across 122 observational studies indexed under Hyperkinesis.

Browse Hyperkinesis studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The sample consists of 50 adults (ages 18-45) with clinical diagnosis of ADHD according to the DSM-IV criteria and 50 age-, sex-, and IQ-matched healthy controls without lifetime diagnosis with ADHD.

Inclusion criteria

  • Subjects aged 18-45, who have clinical diagnosis of a ADHD according to the DSM-IV criteria.

Exclusion criteria

Exclusion Criteria:

  • The subjects will be excluded from the study if they meet any of the following criteria: (1) Comorbidity with diagnoses of autism spectrum disorder, schizophrenia, schizoaffective disorder, delusional disorder, other psychotic disorder, organic psychosis, schizotypal personality disorder, bipolar disorder, depression, severe anxiety disorders or substance use; (2) With neurodegenerative disorder, epilepsy, involuntary movement disorder, congenital metabolic disorder, brain tumor, history of severe head trauma, and history of craniotomy; (3)With visual or hearing impairments, or motor disability which may influence the process of MRI assessment; and (4) Full-scale IQ lower than 80.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
90 participants (actual)
Patient registry
No

Groups and cohorts

  • ADHD group

    Adults with clinical diagnosis of ADHD according to the DSM-IV criteria

  • Control group

    Age-, sex-, and IQ-matched healthy controls without lifetime diagnosis with ADHD

06

What researchers measure

Primary outcomes

  1. Structural neuroimaging

    Using diffusing spectrum imaging (DSI) to assess the structural connectivity in frontostriatal, frontoparietal and other circuitries.

    Time frame: one day

Secondary outcomes

  1. Functional connectivity of the brain circuits

    Using resting-state functional MRI (rsfMRI) to assess the functional connectivity in frontostriatal, frontoparietal and other circuitries.

    Time frame: one day

07

Study locations

1 site
  • National Taiwan Univeristy Hospital
    Taipei, Taiwan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02232464
Lead sponsor
National Taiwan University Hospital
Responsible party
Sponsor
First posted
Sep 5, 2014
Start date
Jan 2014
Primary completion
Dec 2014
Completion
Dec 2014
Last update
Mar 18, 2015

Study contacts

Susan Shur-Fen Gau, MD, PhD
principal investigator · National Taiwan University Hospital & College of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion